InvestorsHub Logo
Post# of 252337
Next 10
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

Re: None

Wednesday, 09/03/2014 11:11:33 AM

Wednesday, September 03, 2014 11:11:33 AM

Post# of 252337
Of all potential Ebola drugs, Brincidofovir is latest stage by far, so I think Chimerix might turn out to be a good Ebola play despite the ho-hum reaction by the market so far today.

Anyone have any idea why it might work though? Ebola is a single-stranded RNA drug, and Brincidofovir targets double-stranded DNA virus.

------
Chimerix's Brincidofovir Has in Vitro Activity Against Ebola
Chimerix Attending World Health Organization Conference in Geneva
Chimerix, Inc.
2 hours ago
GlobeNewswire
DURHAM, N.C., Sept. 3, 2014 (GLOBE NEWSWIRE) -- Chimerix, Inc. (CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today announced in vitro activity of its investigational antiviral brincidofovir (BCV) against the Ebola virus following testing at the Viral Special Pathogens Branch of the US Centers for Disease Control and Prevention (CDC) and the US National Institutes of Health (NIH). Additional assessments of BCV in animal model studies are being conducted through the CDC and NIH.

The company will be attending the World Health Organization's (WHO) two-day conference on September 4-5, 2014 in Geneva, Switzerland. This is the second conference to discuss potential therapies and vaccines that may be appropriate for further study in the current Ebola virus outbreak in Western Africa. On August 11, 2014, WHO convened scientific and medical experts and ethicists from the affected countries to consider the potential use of unapproved therapies and vaccines. As no medicines have received regulatory approval for Ebola virus infection, important topics include clinical trial design, ethics, regulatory approaches and data collection. The conference attendees will be considering available data on investigational agents; for brincidofovir, important considerations include the large safety database of over 1000 patients, the ongoing Phase 3 trials in cytomegalovirus and adenovirus, potential risks and benefits, and the immediate availability of tablets which are stable at room temperature and do not require cold storage.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.